NEWS HIGHLIGHTS
Published Studies Related to Nitroglycerin Injection
Intravenous nitroglycerin for controlled cord traction in the management of retained placenta. [2011.02]
OBJECTIVE: To determine the effect of 200 mug of intravenous nitroglycerin in the release of retained placenta by controlled cord traction... CONCLUSION: Intravenously administered nitroglycerin did not facilitate the release of retained placenta by umbilical cord traction. However, cord traction may be performed longer than 30 minutes to attempt releasing the placenta before operative manual removal is initiated. Copyright (c) 2010 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
Daily low-dose folic acid supplementation does not prevent nitroglycerin-induced nitric oxide synthase dysfunction and tolerance: a human in vivo study. [2010.11]
INTRODUCTION: Continuous treatment with nitroglycerin (GTN) causes tolerance and endothelial dysfunction, both of which may involve endothelial nitric oxide synthase (eNOS) dysfunction... DISCUSSION: The present data demonstrate that daily supplementation with 1 mg folic acid does not prevent the development of GTN-induced eNOS dysfunction or tolerance.
The effect of transdermal nitroglycerine on intrathecal fentanyl with bupivacaine for postoperative analgesia following gynaecological surgery. [2010.03]
Fentanyl is a short-acting synthetic opioid with spinal analgesic properties and dose-dependent side-effects. The analgesic effect of opioids is mediated in part through activation of inhibitory descending pain pathways involving nitric oxide (as a central neurotransmitter) through the NO-cGMP system...
Intravenous nitroglycerin for external cephalic version: a randomized controlled trial. [2009.09]
OBJECTIVE: To estimate whether treatment with intravenous nitroglycerin for uterine relaxation increases the chance of successful external cephalic version... CONCLUSION: Treatment with intravenous nitroglycerin increased the rate of successful external cephalic version in nulliparous, but not in multiparous, women. Treatment with intravenous nitroglycerin appeared to be safe, but our numbers were too small to rule out rare serious adverse effects. LEVEL OF EVIDENCE: I.
Facilitation of radial artery cannulation by periradial subcutaneous administration of nitroglycerin. [2009.09]
PURPOSE: To determine whether subcutaneous administration of nitroglycerin mixed with local anesthetic agent results in effective vasodilation of the radial artery, and whether this technique improves access time and decreases complications... CONCLUSIONS: Subcutaneous administration of nitroglycerin significantly increased radial artery diameter, which can lead to facilitation of catheterization of the radial artery for arteriography and interventions.
Clinical Trials Related to Nitroglycerin Injection
MQX-503 vs Nitroglycerin Ointment: A Pharmacokinetic Comparison in Normal Subjects [Completed]
The purpose of the study is to measure how much nitroglycerin or its metabolites may be found
in the bloodstream when MQX-503 or an FDA approved Nitroglycerin ointment 2% USP is applied
to the skin of healthy subjects.
MQX-503 Applied to the Hand Versus Nitroglycerin Ointment Applied to the Chest: A Pharmacokinetic Comparison [Recruiting]
Nitroglycerin in Non-small Cell Lung Cancer [Recruiting]
Nitroglycerin is a nitric oxide donor which is mainly known as a vasodilating agent used in
ischemic heart disease. It has also been shown to increase tumor blood flow in animal and
human tumors.
The addition of nitroglycerin to chemotherapy in non small cell lung cancer has been shown
to generate very favorable response rates with respect to standard treatment schedules[5].
Theoretically nitroglycerin might reduce resistance to chemotherapy via a plethora of
different effects: better tumor perfusion, direct effects of NO on cancer cells, increase in
activated p53 protein and via an increased blood flow in the tumour with as consequence a
higher drug concentration in the tumor [6] .
In mice, nitric oxide donors such as isosorbide dinitrate have been shown to decrease tumor
hypoxia by better tumor perfusion, which could enhance radiotherapy responses [7].
To date these combined effects have not been tested in humans. In this trial we would like
to demonstrate the effect of nitroglycerin on tumor perfusion and hypoxia in non small cell
lung cancer (using DCE and HX4 scanning), providing a rationale for further study and to
test the effect of combining nitroglycerine to standard treatment of NSCLC
(radiotherapy/chemotherapy).
A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon [Active, not recruiting]
The purpose of this research study is to test the safety, tolerability, and effectiveness of
Topical AmphiMatrix with Nitroglycerin (MQX0503) to relieve Raynaud's symptoms and increase
blood flow to the fingers.
Treatment of Suspected Cholelithiasis With Nitroglycerin [Not yet recruiting]
ABSTRACT: Sublingual nitroglycerin has been advocated for the treatment of acute pain from
suspected symptomatic cholelithiasis. There is, however, no clinical studies that validate
its use. This study is designed to evaluate the efficacy of nitroglycerine in relieving
acute pain of suspected biliary tract origin.
Nitroglycerin is a potent smooth muscle relaxant used for biliary tract dilation during
ERCP, (Chelly, J) and has been recommended for treatment of biliary colic based on
anecdotal experience and small case reports. Nitroglycerin effect is a result of the nitric
oxide component of the medication which acts as a smooth muscle relaxant in vascular,
bronchial, esophageal and biliary smooth muscles. [McGowan(1936), Chelly (1979),Toyoyama
(2001)] The typical dose of nitroglycerin is 0. 4 mg given sublingually in pill form or,
more recently, in a metered spray form. In a case series reported by Hassel (1993), positive
response times ranged from 20 to 60 seconds with duration of action of two to twelve hours.
Sublingual nitroglycerin is most commonly used for treatment of chest pain related to
insufficient cardiac perfusion. It has also been noted to relieve the pain of esophageal
spasms. Nitroglycerin has an excellent safety profile if used in patients with adequate
pretreatment blood pressures. [Newberry (2005), Nitroglycerine (2011), Nitro (2011), Wolters
(2009)] This study proposes to compare sublingual 0. 4 mg doses of nitroglycerin to placebo
for the initial treatment of acute pain from suspected symptomatic cholelithiasis
|
